- Details
- Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients achievi...
|
- Details
- Gerhardt Attard joins Alicia Morgans to discuss a combined analysis from two comparisons in the STAMPEDE platform. Dr. Gerhardt Attard presented a combined analysis from the STAMPEDE platform assessing the role of abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0...
|
- Details
- Alicia Morgans is joined by Felix Feng to discuss molecular determinants associated with response to apalutamide in patients who have nonmetastatic castration-resistant prostate cancer (nmCRPC). SPARTAN, a phase 3 placebo-controlled study in patients (pts) with nmCRPC, showed that apalutamide plus androgen deprivation therapy (ADT) significantly improves metastasis-free survival compared with plac...
|
- Details
- Importance of early intervention in nmCRPC—A discussion with Karim Fizazi, MD, PhD. Darolutamide, an androgen receptor inhibitor, was developed to improve the safety profile of apalutamide and enzalutamide. It has a distinct structure that offers low penetration of the blood-brain barrier as well as other characteristics with the potential for fewer and less toxic adverse events (AEs). The primary...
|
- Details
- Joining Alicia Morgans, MD, MPH, is Pedro Barata, MD, MSc, a co-author of the paper titled, "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability-high (MSI-H) detected by circulating tumor DNA." Dr. Barata provides the background behind the multi-institutional case series explaining that the use of liquid biopsy in identifying metastatic prostate cancer...
|
- Details
- In this discussion, Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a health economics study that was recently published titled, Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. The objective of this study was to evaluate the association of prostate-specific antigen doubling time (PS...
|
- Details
- In this Journal Club, Christopher Wallis and Zachary Klaassen discuss the updated analysis in the most recent publication of the ARAMIS trial. In this publication, overall survival (OS) and all other secondary endpoints were evaluated. The ARAMIS trial looked at the use of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Drs. Wallis an...
|
- Details
- Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall survival w...
|
- Details
- Following a presentation at the ASCO 2020 Annual Meeting, Neal Shore discusses the results of the phase III ARAMIS trial which randomized over 1,500 patients with non-metastatic castration-resistant prostate cancer to 600 mg of darolutamide orally twice daily with ADT, versus a placebo-controlled combination with ADT. The study had a composite endpoint of overall survival and radiographic progress...
|
- Details
- Darolutamide is a structurally unique androgen-receptor antagonist that is approved for the treatment of prostate cancer. ARAMIS is a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer, and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive daroluta...
|
